IP Verse

Bristol Myers Squibb competitive analysis

Latest oppositions filed by Bristol Myers Squibb

Explore patent oppositions filed by Bristol Myers Squibb against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
EP2175884
Combination Therapies Employing Gitr Binding MoleculesGITRMar 13, 2017
EP2242512
Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 26, 2017
EP2100615
Cancer TherapyBIOTEMPUSNov 9, 2016
EP1301538
Artificial Antibody PolypeptidesKOIDESep 9, 2016
EP2287192
Methods For Preventing And Treating Cancer Metastasis And Bone Loss Associated With Cancer MetastasisNOVARTIS VACCINES AND DIAGNOSTICSMay 25, 2016
EP2368913
Glyco-Engineered AntibodiesGREENOVATION BIOTECHSep 23, 2015

Latest patents of Bristol Myers Squibb opposed by its competitors

Explore Bristol Myers Squibb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP4387968
Nov 12, 2025Crystal Forms Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-Carboxamide1
EP3858859
Oct 29, 2025Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)10
EP3837273
Sep 24, 2025Improved Protein Recovery1
EP3377534
Jun 18, 2025Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody3
EP4284796
Apr 16, 2025Crystal Form Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-Carboxamide1
EP4267105
Mar 26, 2025Antibody Compositions And Methods Of Use Thereof2
EP3781132
Mar 20, 2024Apixaban Formulations1
EP3818078
Feb 28, 2024Methods Of Producing Recombinant Proteins6
EP3631454
Sep 13, 2023Treatment Of Lag-3 Positive Tumors2
EP3559230
Sep 6, 2023Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular Genome2

Latest PTAB cases involving Bristol Myers Squibb

Discover the latest PTAB cases involving Bristol Myers Squibb, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 16, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Bristol Myers Squibb

IPR2025-00601Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00602Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00603Feb 28, 2025AMGENBRISTOL MYERS SQUIBBTerminated
IPR2023-00501Feb 6, 2023DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00249Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00252Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2015-01723Aug 13, 2015COALITION FOR AFFORDABLE DRUGS IXBRISTOL MYERS SQUIBBInstitution Denied
IPR2015-01537Jul 2, 2015MOMENTA PHARMACEUTICALSBRISTOL MYERS SQUIBBFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Bristol Myers Squibb with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BRISTOL MYERS SQUIBB6117 - 8
GALENICUM HEALTH SLU4212 - -
GENERICS UK319 - - -
PAJARO36 - - -